A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma

Completed · Phase 2

Conditions studied: Relapsed/Refractory Follicular Non-Hodgkin Lymphoma

In brief

This clinical study examined the safety and efficacy of the combination of zanubrutinib and obinutuzumab versus obinutuzumab alone in adults with follicular lymphoma whose disease returned after or did not respond to prior therapy.

Key facts

Study ID
NCT03332017
Run by
BeiGene
People needed
217
Starts
2017-11-14
Expected to finish
2024-12-27
Last updated by the study team
2026-02-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.